As with the intravenous form, subcutaneous anifrolumab shows clinically meaningful benefits and favorable safety when added ...
Phase 3 trial data show subcutaneous anifrolumab improves BICLA response rates and reduces oral corticosteroid use in ...
US Oncologists anticipate rapid biosimilar uptake – up to 50% of PD-1/PD-L1 eligible patients within the first year – while ...
Dr. Ian Flinn explains in an interview with CURE how Lunsumio VELO (mosunetuzumab) works and its impact on patients with ...
Three years after the accelerated approval of its anti-amyloid Alzheimer’s therapy, Biogen—neck and neck in the market with ...
GlobalData on MSN
Drugmakers welcome FDA’s GLP-1RA suicide warning removal request
The request comes after a two-year review into reported links between GLP-1RAs and psychiatric adverse events.
Single-ascending doses of MAR002 showed a favourable tolerability and safety profile with no drug-related safety signals ...
AJOVY demonstrated efficacy and a consistent safety profile in the SPACE trial, making it the first and only calcitonin gene-related peptide ...
Paolo Ferrigno Product Manager prefilled syringes and cartridges Datwyler Healthcare ...
An autopsy report obtained by News 8 reveals new details in the death of 11-year-old Jacqueline “Mimi” Torres-Garcia, whose ...
At , J. Tracy Watson, MD, spoke about newer concepts and technologies in orthopedic trauma.Among the new concepts is the treatment of neuropathic ankle fractures in patients with diabetes who have ...
The paper, titled, "Weekly Subcutaneous VK2735, a GIP/GLP-1 Receptor Dual Agonist, for Weight Management: Phase 2, Randomized, 13-Week VENTURE Study," was published in Obesity, the peer-reviewed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback